KURA PE Ratio & Valuation,Is KURA Overvalued

KURA Relative Valuation

KURA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KURA is overvalued; if below, it's undervalued.

Historical Valuation

Kura Oncology Inc (KURA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.86 is considered Undervalued compared with the five-year average of -6.76. The fair price of Kura Oncology Inc (KURA) is between 90.89 to 99.46 according to relative valuation methord. Compared to the current price of 10.41 USD , Kura Oncology Inc is Undervalued By 88.55%.

Relative Value

Fair Zone

90.89-99.46

Current Price：10.41

88.55%

Undervalued

-4.06

-1.36

EV/EBITDA

Kura Oncology Inc. (KURA) has a current EV/EBITDA of -1.36. The 5-year average EV/EBITDA is -3.38. The thresholds are as follows: Strongly Undervalued below -9.78, Undervalued between -9.78 and -6.58, Fairly Valued between -0.19 and -6.58, Overvalued between -0.19 and 3.01, and Strongly Overvalued above 3.01. The current Forward EV/EBITDA of -1.36 falls within the Historic Trend Line -Fairly Valued range.

-1.74

EV/EBIT

Kura Oncology Inc. (KURA) has a current EV/EBIT of -1.74. The 5-year average EV/EBIT is -3.51. The thresholds are as follows: Strongly Undervalued below -9.83, Undervalued between -9.83 and -6.67, Fairly Valued between -0.35 and -6.67, Overvalued between -0.35 and 2.82, and Strongly Overvalued above 2.82. The current Forward EV/EBIT of -1.74 falls within the Historic Trend Line -Fairly Valued range.

3.86

Kura Oncology Inc. (KURA) has a current PS of 3.86. The 5-year average PS is 1.08. The thresholds are as follows: Strongly Undervalued below -4.12, Undervalued between -4.12 and -1.52, Fairly Valued between 3.68 and -1.52, Overvalued between 3.68 and 6.28, and Strongly Overvalued above 6.28. The current Forward PS of 3.86 falls within the Overvalued range.

-5.25

P/OCF

Kura Oncology Inc. (KURA) has a current P/OCF of -5.25. The 5-year average P/OCF is -8.19. The thresholds are as follows: Strongly Undervalued below -21.68, Undervalued between -21.68 and -14.93, Fairly Valued between -1.45 and -14.93, Overvalued between -1.45 and 5.29, and Strongly Overvalued above 5.29. The current Forward P/OCF of -5.25 falls within the Historic Trend Line -Fairly Valued range.

-5.61

P/FCF

Kura Oncology Inc. (KURA) has a current P/FCF of -5.61. The 5-year average P/FCF is -9.39. The thresholds are as follows: Strongly Undervalued below -36.63, Undervalued between -36.63 and -23.01, Fairly Valued between 4.23 and -23.01, Overvalued between 4.23 and 17.85, and Strongly Overvalued above 17.85. The current Forward P/FCF of -5.61 falls within the Historic Trend Line -Fairly Valued range.

Kura Oncology Inc (KURA) has a current Price-to-Book (P/B) ratio of 3.67. Compared to its 3-year average P/B ratio of 2.35 , the current P/B ratio is approximately 55.93% higher. Relative to its 5-year average P/B ratio of 2.40, the current P/B ratio is about 52.53% higher. Kura Oncology Inc (KURA) has a Forward Free Cash Flow (FCF) yield of approximately 9.35%. Compared to its 3-year average FCF yield of -4.92%, the current FCF yield is approximately -289.94% lower. Relative to its 5-year average FCF yield of -6.39% , the current FCF yield is about -246.25% lower.

3.67

P/B

Median3y

2.35

Median5y

2.40

9.35

FCF Yield

Median3y

-4.92

Median5y

-6.39

Competitors Valuation Multiple

The average P/S ratio for KURA's competitors is 138.74, providing a benchmark for relative valuation. Kura Oncology Inc Corp (KURA) exhibits a P/S ratio of 3.86, which is -97.22% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of KURA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of KURA in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Kura Oncology Inc (KURA) currently overvalued or undervalued?

What is Kura Oncology Inc (KURA) fair value?

KURA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kura Oncology Inc (KURA) is between 90.89 to 99.46 according to relative valuation methord.

How does KURA's valuation metrics compare to the industry average?

What is the current P/B ratio for Kura Oncology Inc (KURA) as of Dec 15 2025?

As of Dec 15 2025, Kura Oncology Inc (KURA) has a P/B ratio of 3.67. This indicates that the market values KURA at 3.67 times its book value.

What is the current FCF Yield for Kura Oncology Inc (KURA) as of Dec 15 2025?

As of Dec 15 2025, Kura Oncology Inc (KURA) has a FCF Yield of 9.35%. This means that for every dollar of Kura Oncology Inc’s market capitalization, the company generates 9.35 cents in free cash flow.

What is the current Forward P/E ratio for Kura Oncology Inc (KURA) as of Dec 15 2025?

As of Dec 15 2025, Kura Oncology Inc (KURA) has a Forward P/E ratio of -4.06. This means the market is willing to pay $-4.06 for every dollar of Kura Oncology Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Kura Oncology Inc (KURA) as of Dec 15 2025?

As of Dec 15 2025, Kura Oncology Inc (KURA) has a Forward P/S ratio of 3.86. This means the market is valuing KURA at $3.86 for every dollar of expected revenue over the next 12 months.

KURA Valuation